Medistim Logo

Medistim ist ein norwegischer Hersteller und Anbieter von Medizintechnikprodukten. Der Schwerpunkt des Unternehmens liegt auf intraoperativen Qualitätskontrollanwendungen für die Herz-, Transplantations- und Gefäßchirurgie. Innerhalb dieser Nische nimmt Medistim derzeit annähernd eine Monopolstellung ein. Die Kombination aus TTFM-Technologie (transit time flow measurement) und Ultraschallbildgebung machen deren Produkte VeriQ-C sowie MiraQ einzigartig und werden daher auch von den führenden Guidelines für die Anwendung bei Bypass-Operationen empfohlen.   

Unsere Aktienanalysen

News zu Medistim

  • Benefits of Medistim technology in Carotid Endarterectomy published in EJVES
    von Benedicte Meydel am 08/05/2020 um 08:03

    The CIDAC study is a prospective trial comparing high-frequency ultrasound (HFUS, named IDUS in the study) and angiography in 150 patients as intraoperative completion control after removal of plaque in a neck artery, a procedure called carotid endarterectomy (CEA).  The aim of a CEA procedure is to remove plaque that might become a source of The post Benefits of Medistim technology in Carotid Endarterectomy published in EJVES appeared first on Medistim.

  • Results for the First Quarter 2020
    von Benedicte Meydel am 29/04/2020 um 08:07

    Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the full report and presentation below. 1.quarter 2020 report Medistim Q1 2020 presentation   The post Results for the First Quarter 2020 appeared first on Medistim.

  • Company Presentation April 2020
    von Benedicte Meydel am 01/04/2020 um 09:38

    The post Company Presentation April 2020 appeared first on Medistim.

  • Annual Report 2019
    von Benedicte Meydel am 27/03/2020 um 14:28

    We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and installed base. During 2019, the multi center registry study – REQUEST – received a lot of positive attention. Some of The post Annual Report 2019 appeared first on Medistim.

  • The REQUEST study is now published
    von Benedicte Meydel am 24/03/2020 um 09:09

    The REQUEST study is a multicenter, prospective study among 7 international centers performing coronary artery bypass grafting procedures.  The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the rate and reason for surgical changes related to the aorta, in situ conduits, coronary targets, and completed grafts, and the The post The REQUEST study is now published appeared first on Medistim.